John V. Heymach, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘04-‘09), Waun Ki Hong, MD (Former Clinical Investigator Committee Member and Mentor), and colleagues at The University of Texas M.D. Anderson Cancer Center, Houston, reported the identification of two sets of genes that predict response to Tarceva/erlotinib, a targeted therapy used for treatment of certain non-small cell lung cancers. These gene “signatures” were based on the results of the BATTLE clinical trial and will have broad significance, as they will allow physicians to better determine effective treatment regimens for patients. The findings were reported at the AACR 102nd Annual Meeting.
